Ann S LaCasce

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma
    Ann S LaCasce
    Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
    Semin Hematol 45:85-9. 2008
  2. doi request reprint Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma
    Gregory M Cote
    MGH Cancer Center, Boston, Massachusetts 02114 2617, USA
    Biol Blood Marrow Transplant 18:76-83. 2012
  3. doi request reprint Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database
    Ann S LaCasce
    Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA
    Blood 119:2093-9. 2012
  4. pmc Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network
    Ann S LaCasce
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5107-12. 2008
  5. pmc Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant
    Andrew A Lane
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Leuk Lymphoma 53:1130-6. 2012
  6. doi request reprint Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database
    Anita Kumar
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer 118:2944-51. 2012
  7. doi request reprint High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database
    Gregory A Abel
    Brigham and Women s Hospital, Boston, MA, USA
    Leuk Lymphoma 53:1113-6. 2012
  8. pmc Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning
    Philippe Armand
    Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
    J Clin Oncol 26:5767-74. 2008
  9. doi request reprint Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Br J Haematol 160:608-17. 2013
  10. doi request reprint Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy
    Amy M Fox
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 83:277-83. 2012

Detail Information

Publications27

  1. doi request reprint Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma
    Ann S LaCasce
    Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
    Semin Hematol 45:85-9. 2008
    ..Until such trials are mature, we do not recommend using these agents in combination outside of the research setting...
  2. doi request reprint Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma
    Gregory M Cote
    MGH Cancer Center, Boston, Massachusetts 02114 2617, USA
    Biol Blood Marrow Transplant 18:76-83. 2012
    ..Although these outcomes are encouraging, longer follow-up is required and comparison with other traditional ASCT regimens used for patients with non-Hodgkin lymphoma (NHL) is warranted...
  3. doi request reprint Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database
    Ann S LaCasce
    Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02115, USA
    Blood 119:2093-9. 2012
    ..98). RCHOP was inferior to RHCVAD and RCHOP+HDT/ASCR, which had similar PFS and OS. Despite aggressive regimens, the median PFS was 3 to 4 years. Future trials should focus on novel agents rather than comparing current approaches...
  4. pmc Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network
    Ann S LaCasce
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5107-12. 2008
    ..We sought to estimate the impact of expert review in the modern era by comparing final pathologic diagnoses at five comprehensive cancer centers with diagnoses assigned at referring centers...
  5. pmc Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant
    Andrew A Lane
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Leuk Lymphoma 53:1130-6. 2012
    ..0037). Increased vigilance for symptoms of pneumonitis is warranted for patients with prior mediastinal radiation and for younger patients, and dose reduction may be considered for patients who would receive greater than 1000 mg of BCNU...
  6. doi request reprint Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database
    Anita Kumar
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer 118:2944-51. 2012
    ....
  7. doi request reprint High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database
    Gregory A Abel
    Brigham and Women s Hospital, Boston, MA, USA
    Leuk Lymphoma 53:1113-6. 2012
    ..Our results suggest that despite limited data regarding its effect on outcomes, surveillance imaging is prevalent in DLBCL, and a majority of patients receive PET scans at some point during follow-up...
  8. pmc Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning
    Philippe Armand
    Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
    J Clin Oncol 26:5767-74. 2008
    ..We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression...
  9. doi request reprint Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Br J Haematol 160:608-17. 2013
    ....
  10. doi request reprint Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy
    Amy M Fox
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 83:277-83. 2012
    ..This study sought to quantify the risk of radiation pneumonitis (RP) in Hodgkin lymphoma (HL) patients receiving mediastinal radiation therapy (RT) and to identify predictive factors for RP...
  11. doi request reprint Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients
    Yi Bin Chen
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    Leuk Lymphoma 51:789-96. 2010
    ..In conclusion, patients who fail R-CHOP appear to benefit from ASCT, but they may have a worse prognosis compared to patients who fail CHOP alone...
  12. pmc Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia
    Philip C Amrein
    Massachusetts General Hospital Cancer Center, Medical Oncology and Department of Biostatistics, Dana Farber Cancer Institute, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 17:2977-86. 2011
    ..Chronic lymphocytic leukemia (CLL) cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the activity of dasatinib in patients with relapsed CLL...
  13. pmc A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Haematologica 98:964-70. 2013
    ..This study is registered at ClinicalTrials.gov (Identifier:00330252)...
  14. doi request reprint Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy
    George P Canellos
    Medical Oncology Hematology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:1611-5. 2010
    ..This study examines the impact of chemotherapy alone in treatment of limited-stage, nonbulky HL, radiation therapy eliminated from primary treatment...
  15. doi request reprint Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis
    Alfred Ian Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
    Cancer 116:3835-42. 2010
    ..The majority of patients with Hodgkin lymphoma (HL) achieve disease remission after primary therapy. To the best of the authors' knowledge, no consensus exists for postremission surveillance imaging...
  16. doi request reprint Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database
    Michelle E Kho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 113:3209-12. 2008
    ..Clinical trials and outcomes studies often rely on nonphysicians to abstract complex data from medical records, but the reliability of these data are rarely assessed...
  17. pmc Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
    Jeffrey A Barnes
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Haematologica 98:615-9. 2013
    ..In conclusion, everolimus in combination with rituximab is well tolerated and demonstrates activity in relapsed diffuse large B-cell lymphoma. Further studies of this combination are warranted...
  18. ncbi request reprint Post-transplant lymphoproliferative disorders
    Ann S LaCasce
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncologist 11:674-80. 2006
    ..Prognosis is variable, due in part to the heterogeneity of the disease, which ranges from reactive plasmacytic hyperplasia to aggressive monoclonal disease...
  19. pmc Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 143:361-8. 2008
    ..026). We conclude that familial aggregation of LPDs is common among newly diagnosed patients, varies significantly by diagnosis and contributes meaningfully to the population disease burden...
  20. ncbi request reprint Primary mediastinal large B-cell lymphoma
    Jason E Faris
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA
    Clin Adv Hematol Oncol 7:125-33. 2009
    ....
  21. pmc Biology of double-hit B-cell lymphomas
    R Coleman Lindsley
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Curr Opin Hematol 19:299-304. 2012
    ..This review summarizes the recent literature regarding the clinical and pathologic features of double-hit lymphomas and outlines current questions about the most accurate and inclusive definition of the disease...
  22. doi request reprint Nodular lymphocyte predominant Hodgkin lymphoma
    Alfred Ian Lee
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Oncologist 14:739-51. 2009
    ..For relapsed disease, treatment options include the salvage therapies used in classical HL, and rituximab...
  23. pmc Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:418-25. 2008
    ..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population...
  24. ncbi request reprint Enzastaurin
    Yi Bin Chen
    Dana Farber Cancer Institute, Massachusetts General Hospital, GRB 740, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Investig Drugs 17:939-44. 2008
    ..Enzastaurin is a novel antineoplastic and antiangiogenic agent that acts through inhibition of protein kinase C (PKC)...
  25. ncbi request reprint Lymphoma: risk and response after solid organ transplant
    Caron A Jacobson
    Division of Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 24:936-44. 2010
    ..Further clinical investigation, including randomized controlled trials, will be important in reaching this goal...
  26. ncbi request reprint Non-Hodgkin's lymphomas
    Andrew D Zelenetz
    J Natl Compr Canc Netw 6:356-421. 2008
  27. ncbi request reprint Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology
    Andrew D Zelenetz
    J Natl Compr Canc Netw 4:258-310. 2006